Initiated Sector Outperform X

BBIO BridgeBio Pharma

Scotiabank

Initiated Perform X

BBIO BridgeBio Pharma

Oppenheimer

Initiated Overweight X

BBIO BridgeBio Pharma

Piper Sandler

$46

Resumed Outperform X

BBIO BridgeBio Pharma

Raymond James

$45

Initiated Market Perform X

BBIO BridgeBio Pharma

BMO Capital Markets

$37

Initiated Overweight X

BBIO BridgeBio Pharma

Wells Fargo

$58

Initiated Buy X

BBIO BridgeBio Pharma

Citigroup

$42

Initiated Overweight X

BBIO BridgeBio Pharma

Cantor Fitzgerald

$50

Downgrades Buy Hold X

BBIO BridgeBio Pharma

Jefferies

$24 $33

Initiated Outperform X

BBIO BridgeBio Pharma

Evercore ISI

$40

Initiated Outperform X

BBIO BridgeBio Pharma

Cowen

Initiated Buy X

BBIO BridgeBio Pharma

UBS

$80

Resumed Overweight X

BBIO BridgeBio Pharma

JP Morgan

$78

Resumed Buy X

BBIO BridgeBio Pharma

Goldman

$83

Reiterated Buy X

BBIO BridgeBio Pharma

H.C. Wainwright

$64 $87

Initiated Outperform X

BBIO BridgeBio Pharma

Raymond James

$36

Initiated Outperform X

BBIO BridgeBio Pharma

BMO Capital Markets

$49

Initiated Buy X

BBIO BridgeBio Pharma

Goldman

$42

Initiated Buy X

BBIO BridgeBio Pharma

Jefferies

$38

Initiated Overweight X

BBIO BridgeBio Pharma

JP Morgan

$38

Initiated Overweight X

BBIO BridgeBio Pharma

Piper Jaffray

$50

Initiated Outperform X

BBIO BridgeBio Pharma

SVB Leerink

$34

BBIO  BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. finds, develops, and delivers various medicines for genetic diseases. The company has a pipeline of 15 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology. Its principal products in development programs include BBP-265, an oral small molecule transthyretin (TTR) for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers, as well as for the treatment of achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer product candidate for the treatment of congenital adrenal hyperplasia caused by 21OHD; and BBP-454, a preclinical development program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company was founded in 2015 and is headquartered in Palo Alto, California.